| Name | Title | Contact Details |
|---|
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.
Oregon Bioscience Association (@OregonBio) members are involved in cutting edge research and development of innovative health care, agricultural and environmental bio technologies. Our corporate members range from entrepreneurial start ups developing a first product to large multinationals. We also represent the state`s biotech research institutions, service providers to the industry and academic centers of learning. A unified voice for the Oregon bioscience community the Oregon Bio: * Represents the bioscience research to commercialization process * Helps to accelerate the growth of the biosciences industry in all parts of Oregon * Enhances the state`s bioscience business and research climate * Helps attract and retain bioscience talent and companies. * Vigorously works to improve the quality of the bioscience workforce * Partners with government at all levels to achieve its goals.
Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine.
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWounds first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Companys lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWounds pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com
Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of CNS disorders. Axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. The company is based in New York City.